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Abstract
The Na–K–2Cl cotransporter plays important roles in cell ion homeostasis and volume control and is particularly important in mediating
the movement of ions and thus water across epithelia. In addition to being affected by the concentration of the transported ions, cotransport is
affected by cell volume, hormones, growth factors, oxygen tension, and intracellular ionized Mg2 + concentration. These probably influence
transport through three main routes acting in parallel: cotransporter phosphorylation, protein–protein interactions and cell Cl concentration.
Many effects are mediated, at least in part, by changes in protein phosphorylation, and are disrupted by kinase and phosphatase inhibitors,
and manoeuvres that reduce cell ATP content. In some cases, phosphorylation of the cotransporter itself on serine and threonine (but not
tyrosine) is associated with changes in transport rate, in others, phosphorylation of associated proteins has more influence. Analysis of the
stimulation of cotransport by calyculin A, arsenite and deoxygenation suggests that the cotransporter is phosphorylated by several kinases
and dephosphorylated by several phosphatases. These kinases and phosphatases may themselves be regulated by phosphorylation of residues
including tyrosine, with Src kinases possibly playing an important role. Protein–protein interactions also influence cotransport activity.
Cotransporter molecules bind to each other to form high molecular weight complexes, they also bind to other members of the cation–chloride
cotransport family, to a variety of cytoskeletal proteins, and to enzymes that are part of regulatory cascades. Many of these interactions affect
transport and may override the effects of cotransporter phosphorylation. Cell Cl may also directly affect the way the cotransporter functions
independently of its role as substrate.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The Na–K–2Cl cotransporter plays important roles in
cell ion homeostasis and volume control. It is particularly
important in mediating the movement of ions and thus water
across epithelia. In these cells, the transport of ions across the
basolateral and apical membranes must be very carefully
controlled and coordinated to prevent massive changes in ion
concentration and cell volume during secretion and reab-
sorption. The primary control of both processes appears to be
directed at changing the activity of Cl and K+ channels.
These channels rapidly mediate the movement of large
numbers of ions into or out of epithelial cells, and these
fluxes must be balanced by an equivalent flux involving
appropriate carriers and pumps. The Na–K–2Cl cotrans-
porters are important providers of these balancing ion fluxes.
Ussing [1] was among the first to suggest the existence of
cotransport in epithelia and also suggested that the trans-
porter is regulated by volume and cell Cl concentration.
Several excellent reviews deal with the discovery, proper-
ties and regulation of the cotransporter [2–5]. In this paper, I
will briefly review the properties of the cotransporter and
will then examine how phosphorylation affects transporter
function and explore the possibility that the transporter forms
high molecular weight complexes that are significant in its
regulation. To do this, I will draw on information from the
study of red cells, a model system that has long provided
insight into epithelial function [6].
2. Na–K–2Cl cotransporter isoforms
Isoforms of the Na–K–2Cl cotransporter are widely
distributed among animal cells. Most cells contain NKCC1
(or BSC2) and this is often referred to as the housekeeping
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or secretory isoform. A separate gene product, NKCC2 (or
BSC1), is found mainly in the mammalian kidney where it
is involved in the reabsorption of Na+, K+ and Cl from
the fluid in the thick ascending limb of Henle’s loop
(TAL). It is often referred to as the reabsorptive isoform.
The gene (Slc12a2) for the human form of NKCC1 (on
chromosome 5q23.2) encodes for a 1212 amino acid protein
with a predicted molecular weight of about 132 kDa. The
protein is glycosylated and runs as a smear with an apparent
molecular weight of 160–170 kDa on sodium dodecyl
sulfate polyacyrlamide gels (SDS-PAGE) [7]. A similar
picture is found for NKCC1 in other species, though the
protein may have a slightly higher apparent molecular
weight (up to 190 kDa) [8–12]. Deglycosylation with N-
glycanase reduces the apparent molecular weight of
NKCC1 to about 135 kDa, close to the weight predicted
from cDNA [13]. A splice variant of NKCC1 has been
observed in the brain [14]. It lacks a short peptide from the
carboxy-terminal that codes for a protein kinase A (PKA)
consensus site.
The gene for human NKCC2 (Slc12a1 on chromosome
15q15–q21.1) encodes for a shorter, 1099 residue protein,
with a predicted molecular weight of 121 kDa [15]. This
runs at an apparent weight of 150–160 kDa on SDS gels
due to glycosylation [16]. A total of six splice variants of
NKCC2 have been identified. There are three splice variants
of full-length NKCC2 expressed in different parts of the
TAL [15,17]. The proteins differ in a small region including
part of transmembrane domain (TM) 2 that is believed to be
involved in determining the Na+, K+ and Cl binding
affinities of the transporter. Variant F is found in cells in
the outer medullary region of the TAL and has the lowest
affinities for Na+, K+ and Cl (and possibly the highest
turnover rate), variant A is found in cells both in the outer
medullary and cortical TAL, and has higher affinities for the
transported ions. Variant B is found in the macula densa
region of the kidney and has the highest Cl affinity.
Carboxy-terminal-truncated versions of splice variants A,
B and F have been identified in mouse kidney (770
residues), and these have an apparent molecular weight of
about 120 kDa [18].
3. The cation–chloride cotransporter family
The Na–K–2Cl cotransporters are part of a large super-
family of transporters—the cation–chloride cotransporter
(CCC) family [19–21]. This family includes the K+-inde-
pendent Na–Cl cotransporter (NCC or TSC) found in the
distal convoluted tubule of the kidney, and which is respon-
sible for the electroneutral reabsorption of Na+ and Cl. This
transporter is not affected by bumetanide but is inhibited by
thiazide diuretics. Four Na+-independent, K–Cl cotransport-
ers have been described (KCC1, KCC2, KCC3 and KCC4).
These transporters produce an electroneutral loss of K+ and
Cl from cells, can play an important role in regulatory
volume decrease, and are inhibited by furosemide and by
high doses of bumetanide. Recently a new CCC family
member has been identified. This protein does not appear
to transport ions itself but inhibits NKCC with which it
associates. It is called the cation–chloride cotransporter-
interacting protein (CIP1) [20].
4. General properties of Na–K–2Cl cotransporters
The cotransporter usually moves 1 Na+, 1 K+ and 2 Cl
ions across cell membranes in an electroneutral fashion, so
that operation of the transporter neither generates a current
nor is affected by membrane potential [2,4,22–24]. There
are some possible exceptions to this stoichiometry. NKCC1
from squid axons appears to transport 2Na+:1K+:3Cl
[4,25], and a truncated form of NKCC2 may transport
1Na+:1Cl independently of K+ [26]. Ions bind to the
cotransporter in a strictly ordered sequence, so that from
the outside of the cell, binding of Na+ is followed by Cl,
then K+ and finally Cl [24]. At the inside surface, the
ions are again released in an ordered sequence, following
the dictum, first on, first off, also known as glide sym-
metry [24]. As access to the ion binding sites changes
from the exterior cell surface to the internal surface, the
ions become temporarily occluded within the transporter
[27]. A key diagnostic feature of Na–K–2Cl cotransport-
ers is their very high sensitivity to inhibition by bumeta-
nide and other loop diuretics. NKCC2 is more sensitive to
inhibition by bumetanide than NKCC1 [4,28]. The trans-
porter can move ions in both directions across the mem-
brane but the net direction of transport is governed by the
combined chemical gradients for Na+, K+ and (Cl)2.
Thus, when the transporter is activated, it tends to cause
the entry of these ions into cells, which is followed by the
movement of water causing cell volume to increase.
Activation of the cotransporter can thus play an important
role in the regulatory volume increase (RVI) that occurs
when some cells are shrunk. Much effort has been directed
at trying to identify how cells detect the change in volume
and produce an appropriate change in cotransport rate
[29–32].
Although the transporter is not a primary active trans-
porter and does not consume ATP [22], it is inhibited in cells
whose ATP content has been reduced [33–35]. This need for
ATP reflects an important role for phosphorylation in
regulating transport [36]. However, the transporter is capa-
ble of secondary active transport, for instance moving Cl or
K+ into cells using the energy in the Na+ gradient. An
important step in establishing that the cotransporter could
transport Cl in red cells, and was not simply Cl-depend-
ent, was the finding that Cl moving down its electro-
chemical gradient could drive Na+ up its gradient [23].
The transporter thus plays an important role in regulating
cell Cl and K+ content, and cells can lose K+ and Cl when
treated with loop diuretics.
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The cotransporter plays a particularly important role in
the movement of ions across epithelia. NKCC1 is usually
found in the basolateral membranes and causes the uptake
of Na+, K+ and Cl from the serosal solution into the cells.
The Na+ and Cl can then be secreted by a variety of
mechanisms across the apical membrane. NKCC2 is found
in the apical membranes of TAL cells, and is responsible
for reabsorbing Na+, K+ and Cl from the urine. The K+ is
recycled back into the urine through K+ channels, thus
making the urine electrically positive with respect to the
serosal side. This potential then drives the reabsorption of
cations, including Mg2 +, through the tight junctions. In the
TAL, we see how the use of splice variants allows match-
ing of transporter ion affinities (and possibly transport
rates) to the decreasing ion concentrations in the urine as
it flows from medulla to cortex [17]. NKCC2 splice variant
B is thought to play an important role in the macula densa’s
ability to sense the Na+ and Cl concentrations in the distal
urine and send information back to the afferent arteriole
(tubulo-glomerular feedback).
5. Cotransporter structure
Sequence and hydropathy analysis of NKCC1, together
with information from antibody accessibility studies suggest
that NKCC1 has 12 transmembrane domains with large
cytoplasmic carboxy- and amino-termini, and has an extrac-
ellular domain between TM7 and 8 that is glycosylated
[7,8,13,37]. This picture has been recently confirmed by
studying the way putative transmembrane domains are
expressed in an in vitro translation system [38]. Most of
our knowledge about which parts of the Na–K–2Cl
cotransporter are involved in ion and bumetanide binding
comes from studies of NKCC1 from shark rectal gland and
human colon cells, and in particular by studying the proper-
ties of chimeric proteins formed by joining sections of the
human and shark transporters, and also from site-directed
mutagenesis [28,39–42]. Regions in TM2, 4 and 7 deter-
mine the Na+, K+ and Cl affinities of the transporter while
these same regions, together with regions in TM11 and 12,
determine bumetanide binding affinity. This latter finding
brings into question the idea that bumetanide inhibits the
cotransporter by simply binding to the Cl site [43], clearly
other regions of the transporter are involved too.
Experiments with 32P show that the cotransporter itself
is phosphorylated at multiple sites when transport is
activated by a variety of different stimuli [11,36,44–47].
Analysis of the primary sequence of the transporter sug-
gests that there are many potential targets for protein
kinases, depending on the isoform and the species. How-
ever, as we will see later, it has proved extremely difficult
to identify the kinases and phosphatases that are respon-
sible for regulating cotransporter phosphorylation. An
interesting recent development is the identification a highly
conserved sequence in the cytoplasmic amino-terminal
domain of the cotransporter that binds the catalytic subunit
of protein phosphatase 1 [48]. The cotransporter appears to
function as its own scaffolding to bring together regulatory
enzymes and their targets.
6. Regulation of transport
Until their binding sites are saturated, transport rate will
depend on the concentrations of the transported ions. In
addition, a number of other factors influence transport rate.
Cotransport is usually stimulated by cell shrinkage, and in
a few cases by cell swelling [2,49], it is stimulated by
hormones such as noradrenaline and vasopressin [2],
growth factors including serum [2,50], reduced oxygen
tension [51,52], increased intracellular Mg2 + concentration
[53], and reduced intracellular Cl acting at a site separate
from the transport site [54,55]. These factors influence
transport through three main routes acting in parallel:
cotransporter phosphorylation, protein–protein interactions
and probably a direct effect of cell Cl concentration itself.
Inhibition of protein kinases and phosphatases, and reduc-
tion in cell ATP content interfere with the cell’s ability to
respond appropriately to many of these stimuli, suggesting
that changes in protein phosphorylation are, at least partly,
involved in detection, signal transduction and response to
these stimuli [34,35,51,52,56–61]. As phosphorylation of
the transporter itself has been shown to correlate with
transport rate under a number of conditions, it is tempting
to speculate that phosphorylation of the cotransporter is the
final common pathway through which transport is regu-
lated [9–11,36,44,45]. However, a number of careful stu-
dies have shown that transport may be influenced by
protein–protein interactions either within the membrane
or with elements in the cytoskeleton. Conditions can be
found where transport rate changes independently of
cotransporter phosphorylation [10] (see Section 9).
Analysis of the effects of cell volume on cotransport are
complicated by the difficulty in separating direct effects of
cell volume, perhaps mediated by changes in the structure
of the cytoskeleton [62], from secondary effects due to
subtle changes in cell Cl content. For instance, the
activation of secretion may start with the opening of apical
Cl channels and the loss of cell Cl and water. The
question is whether the activation of cotransport that
follows is due to the reduction of Cl or of cell volume.
Evidence can be found supporting a primary role for cell
Cl [5,55] or cell volume [63].
7. Role of phosphorylation
The first indication that protein phosphorylation might
be important in regulating cotransport came from studies
on the effects of starvation, metabolic depletion and
internal perfusion of cells [33,34,64–68]. On the basis of
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these studies, it was suggested that the cotransporter itself
or an associated regulatory protein might be activated by
phosphorylation [69–72]. As described above, it is now
known that the cotransporter is phosphorylated under a
variety of conditions that stimulate cotransport. Key stud-
ies revealed that it is phosphorylated on at least five sites
which include serine and threonine residues in the cyto-
plasmic amino and carboxy-termini. There is no evidence
for regulatory phosphorylation of tyrosine [36,45]. Impor-
tantly, several different means of stimulating transport were
shown to produce identical patterns of phosphorylation as
judged by phosphopeptide mapping [45]. This finding
gave credence to the idea that regulatory phosphorylation
of the cotransporter is carried out by a single kinase.
However, it still needs to be established whether phosphor-
ylation at the different sites have equivalent effects on
transport, whether there are additive or inhibitory effects,
and importantly whether phosphorylation is necessary for
transport.
7.1. Experiments on ferret red cells
In order to address some of these issues, we have been
examining the properties of Na–K–2Cl cotransport in ferret
red cells. These cells are a useful model in which to study
the properties of the mammalian Na–K–2Cl cotransporter
[59,67,73]. They have a very high resting cotransport rate
and more than 90% of K+ uptake is though the transporter.
Measurement of bumetanide-sensitive 86Rb (tracer for K+)
uptake provides a robust assay for cotransporter activity. In
addition, there is little contamination of the fluxes by K+–
K+ exchange as these cells have a low K+ content [24,74].
7.2. A one-kinase/one-phosphatase model
The simplest model of cotransporter regulation by phos-
phorylation assumes the transporter is phosphorylated (at
multiple sites) and dephosphorylated by one kinase (CT-
kinase) and one phosphatase (CT-phosphatase). Regulation
of transport would then focus on the regulation of these two
enzymes. If this were so, it should be possible to inhibit all
cotransport activity by inhibiting the kinase (assuming that
the transporter must be phosphorylated to be active), and it
should be possible to demonstrate maximal stimulation by
inhibiting the phosphatase (see Fig. 1).
7.3. Calyculin A maximally stimulates cotransport
Cotransport in ferret red cells is maximally activated
within a few minutes by the potent protein phosphatase
inhibitor, calyculin A, and this activity is then maintained
[75]. This implies that the cells contain a highly active CT-
kinase, the activity of which is revealed by the addition of
calyculin. Thus, steady-state levels of phosphorylated and
dephosphorylated cotransporter are maintained by a highly
active CT-kinase and phosphatase. Studies of the potencies
of a range of phosphatase inhibitors on transport in intact
cells, and more compellingly, on NKCC1 dephosphoryla-
tion in membranes, suggest that calyculin stimulates cotran-
sport by inhibiting protein phosphatase 1 rather than protein
phosphatase 2A [48,55,58]. Treatment of ferret red cells
with cyclosporin A causes only minor transport stimulation
suggesting that protein phosphatase 2B plays a minor role
in cotransport regulation in these cells, and is consistent
with this transporter’s insensitivity to changes in Ca2 +
concentration [75,76].
In red cells, calyculin A causes maximal cotransport
stimulation that is stable over long periods [45,58,75].
However, in Ehrlich ascites cells, stimulation is transient,
perhaps being offset by events caused by the gradual cell
swelling also caused by calyculin [61]. This inactivation can
be delayed by shrinking the cells. These findings suggest
either, that another phosphatase becomes active, or that
interactions with the cytoskeleton, or cell Cl (see Sections
8 and 9), override the effects of transporter phosphorylation.
7.4. Non-specific inhibition of kinases by removing cell
Mg2+ reveals significant residual cotransport
In order to inhibit kinases non-specifically in a cell
extract it is normal practice to reduce Mg2 + to sub-micro-
molar levels by adding a chelator such as EDTA. This can
also be achieved in intact red cells by treating them with the
ionophore A23187 in the presence of extracellular EDTA
[77]. Under these conditions, the cotransporter continues to
function at about 15–20% of its maximal rate (equivalent to
about 50% resting rate) [53] despite the fact that all kinases
should be inactive. The fact that cotransport continues at a
significant level suggests that, either some cotransporter
molecules can operate when dephosphorylated, or that some
of the cotransporter is trapped in a partially phosphorylated,
partially active state, in the absence of Mg2 +. If the latter is
true, then at least some of the phosphorylated cotransporter
molecules are probably dephosphorylated by a Mg2 +-sensi-
tive protein phosphatase, otherwise, residual phosphatase
activity should lead to total dephosphorylation and total loss
of activity. The alternative possibility, that two forms of the
cotransporter may exist, is supported by the finding of
doublets (approximately 140 and 160 kDa) in Western blots
of membranes probed with anti-cotransporter antibodies
(T4, see Ref. [78]) [50,79].
Fig. 1. One-kinase/one-phosphatase model for the regulation of cotransport.
In this model, only phosphorylated cotransporter (COT-P) is active. The
cotransporter (COT) is phosphorylated at multiple sites by a single
cotransporter kinase (CT-kinase) and dephosphorylated by a single
cotransporter phosphatase (CT-PPase).
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7.5. A specific kinase inhibitor that totally inhibits cotran-
sport has yet to be found
We have not been able to find a kinase inhibitor that
inhibits all the cotransport activity in ferret red cells [75,80].
Inhibitors of PKA, PKC, PKG and casein kinase II have
little effect on transport. Of the kinase inhibitors tested,
staurosporine, genistein and PP1 (4-amino-5-(4-methyl-
phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimadine), were the
most effective at inhibiting cotransport (inhibit about 40–
50% resting activity), but were no more effective than
Mg2 +-removal. In addition, the use of these inhibitors in
combination with each other, or with Mg2 +-removal, was no
more effective than the agents alone [75]. Again, the
simplest explanation for these findings is that some cotrans-
porter molecules do not need to be phosphorylated to be
active. Clearly, it is important to establish whether this is so.
In order to assess this, the cotransporter was immunopreci-
pitated from ferret red cells under a variety of conditions
using antibody T4. Analysis of the immunoprecipitate’s
incorporation of 32P and reactivity to phospho-specific
antibodies suggests that the cotransporter is phosphorylated
under resting conditions and that this increases when cells
are treated with calyculin. Phosphorylation is reduced when
cells are treated with PP1, but is still easily detectable
(Flatman and Matskevich, unpublished observations). This
suggests that the residual transport seen in cells treated with
PP1 (and the same probably applies to those treated with
staurosporine or Mg2 +-removal) is associated with a phos-
phorylated rather than with an unphosphorylated form of the
cotransporter. Residual phosphorylation of the cotransporter
in the presence of staurosporine has also been seen in
salivary glands [47].
If we make the assumption that only phosphorylated
cotransporter is active and that one kinase and phosphatase
are responsible for regulatory phosphorylation, it follows
that a potent CT-kinase inhibitor has not yet been found,
and an alternative explanation must be found for the
partial inhibition of transport by staurosporine, genistein
and PP1. One possibility is that these compounds inhibit a
kinase that phosphorylates and inhibits the CT-phosphatase
(Fig. 2). Thus, in the presence of staurosporine or PP1, the
CT-phosphatase becomes more active, and more, but not
all, of the cotransporter becomes dephosphorylated and
inactive.
It is interesting to note that the kinase inhibitors that are
most effective in reducing transport all inhibit tyrosine
kinases [81–83]. Mg2 +-removal is the least selective way
of inhibiting kinases, whereas PP1 is probably the most
selective, and inhibits Src kinases [83], perhaps suggesting
an important role for Src kinases in the regulation of
cotransport. Yet all these agents reduce transport to about
the same extent. Transport rate correlates with changes in
serine/threonine phosphorylation of the cotransporter and
not with tyrosine phosphorylation [36,45]. This supports
the idea that these inhibitors are acting indirectly perhaps
by preventing phosphorylation of a CT-kinase or phospha-
tase. Interestingly, tyrosine phosphatase inhibitors like vana-
date and bpV(phen) have little effect on transport in ferret red
cells [35,75].
Analysis of the actions of genistein, particularly in
association with calyculin suggests that this agent may be
acting as a direct inhibitor of the Na–K–2Cl cotransporter
(like bumetanide) as well as a tyrosine kinase inhibitor
[75,80].
7.6. Combined use of kinase and phosphatase inhibitors
Examination of the effects of the sequential treatment of
cells with kinase and phosphatase inhibitors on 86Rb uptake
provides insight into the mechanisms regulating phosphory-
lation. Treatment of cells with PP1, staurosporine or Mg2 +-
removal before calyculin almost completely prevents stim-
ulation of transport, whereas addition of these agents after
calyculin causes a small (about 30%) reduction in the
stimulated rate [75]. Similar results for the interactions
between calyculin and staurosporine have been observed in
duck and turkey red cells [45,51]. Assuming that only
phosphorylated cotransporter is active, and that there is a
single kinase and phosphatase, this implies that calyculin
inhibits a phosphatase that dephosphorylates the CT-phos-
phatase rather than inhibiting the CT-phosphatase itself (Fig.
2). In addition, the CT-phosphatase must be Mg2 +-sensitive
in order to explain continued transport in the absence of
Mg2 +.
The suggestion that calyculin does not directly inhibit the
CT-phosphatase is controversial. In support of direct inhib-
ition is the recent finding that NKCC1 has a binding site for
the catalytic subunit of protein phosphatase 1 [48]. The
Fig. 2. A one-kinase/one-phosphatase model to account for the effects of
calyculin, arsenite and kinase inhibitors [80]. If only phosphorylated
cotransporter is active, the kinase inhibitors, staurosporine, PP1 and
genistein inhibit a kinase that phosphorylates and inhibits CT-phosphatase
(to form inactive CT-PPase-P). Calyculin A inhibits a phosphatase (PPase)
that dephosphorylates and activates CT-PPase. Arsenite indirectly activates
CT-kinase. Other abbreviations as in Fig. 1.
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presumption here is that protein phosphatase 1 binds to the
cotransporter to improve access to phosphate groups on the
cotransporter itself. However, it is possible that the binding
of the phosphatase to the cotransporter allows it to
dephosphorylate another phosphatase that is part of the
regulatory cascade. Evidence in favour of this latter view
may come from work on membranes prepared from
salivary glands [47]. If protein phosphatase 1 forms a tight
complex with the cotransporter and is capable of dephos-
phorylating the cotransporter, we would expect the addi-
tion of calyculin to these membranes to maintain the
cotransporter in a phosphorylated state. However, calyculin
did not prevent dephosphorylation of the transporter,
whereas vanadate did.
7.7. Stimulation by arsenite
Cotransport in ferret red cells is also maximally stimu-
lated by arsenite ions [80]. In this case, staurosporine, PP1
and Mg2 +-removal both prevent stimulation when added
before arsenite and reverse the stimulation when added after
arsenite. Treatment of cells with a combination of arsenite
and calyculin produce maximal stimulation even in cells
that have been stored for a few days (a time when stim-
ulation by either calyculin or arsenite alone has started to
wane). The kinase inhibitor PP1 does not prevent nor
reverse the stimulation caused by the combination of caly-
culin and arsenite, and staurosporine only has a minor
effect. On the other hand, Mg2 +-removal completely pre-
vents stimulation by this combination, and causes a small
amount of inhibition when added later. In order to explain
the effects of arsenite, both alone, and in combination with
calyculin, in terms of the one-kinase/one-phosphatase
model, it is necessary to propose that arsenite stimulates
the CT-kinase, probably indirectly (Fig. 2) [80].
The finding that cotransport activity returns to resting
level in cells that have been stimulated with arsenite and are
then Mg2 +-depleted is hard to explain with the proposed
model. Mg2 +-removal would be expected to leave transport
rates high as the phosphatase is probably more sensitive to
Mg2 +-removal than the kinase. A more plausible explan-
ation is that the cotransporter is dephosphorylated by more
than one phosphatase. The same suggestion has been made
to explain the response of the cotransporter to a range of
pharmacological manipulations in Ehrlich cells [61].
7.8. Cotransporter phosphorylation may involve multiple
kinases and phosphatases
More problems for the one-kinase/one-phosphatase mo-
del arise when attempting to analyse the effects of deoxy-
genation on the cotransporter. Deoxygenation maximally
stimulates Na–K–2Cl cotransport [51,52], and this stimu-
lation is both prevented and reversed by PP1, staurosporine
and Mg2 +-removal, just as was seen with arsenite [52].
However, the effects of arsenite can be distinguished from
those of deoxygenation. If deoxygenation and arsenite affect
cotransport in identical ways, PP1 should have little effect
on transport stimulated by the combined effects of deoxy-
genation and calyculin (compare with its effect on the
combined action of arsenite and calyculin). When the ex-
periment was carried out, PP1 was found to reduce transport
by more than 30%. Also if deoxygenation acts like arsenite,
the combined effects of these treatments should be indis-
tinguishable from either alone. In this case, experiments
revealed that addition of PP1 to cells after transport had
been stimulated by the combination of arsenite and deoxy-
genation, caused only a minor reduction in transport rate
(Flatman, unpublished results).
In order to encompass all these findings, it is probably
necessary to abandon the idea that cotransporter phosphor-
ylation is maintained by a single kinase and phosphatase.
The data are more consistent with the idea that deoxygena-
tion either activates a kinase that is quiescent in oxygenated
cells, or causes a conformational change that allows a kinase
access to appropriate sites on the cotransporter. There is
evidence that deoxygenation causes profound changes in
both membrane protein phosphorylation, and in the associ-
ation of structural proteins and enzymes with integral
membrane proteins [84–87]. The data also suggest that
PP1 and staurosporine inhibit (indirectly) the kinase acti-
vated by deoxygenation.
Models for transport regulation involving multiple kin-
ases and phosphatases can be complex (Fig. 3). It is not clear
whether phosphorylation by one of the CT-kinases is
reversed by one particular phosphatase or whether it is
reversed by the action of several phosphatases, and vice
versa. Yet despite these problems some conclusions can be
made. For instance, deoxygenation probably promotes phos-
phorylation by a kinase that is distinct from the kinase active
at rest and revealed by treating cells with calyculin. Once we
abandon the one-kinase/one-phosphatase model, it is possi-
ble to attribute some of the actions of PP1 and staurosporine
to inhibition (probably indirect) of a CT-kinase active at rest
and a CT-kinase activated by deoxygenation. We can also
propose that protein phosphatase 1 directly dephosphorylates
some cotransporter molecules, in which case the correspond-
ing kinase is probably inhibited by staurosporine and PP1.
On the other hand, if some cotransporter molecules are
dephosphorylated by a Mg2 +-sensitive protein phosphatase
(2C? see Ref. [88]), these are probably phosphorylated by a
kinase insensitive to staurosporine and PP1. This would
explain how the cotransporter retains similar partial activity
in the presence of kinase inhibitors and in the absence of
Mg2 + (and would correspond to activity associated with
COT-P3 in Fig. 3).
Multiple kinase models also explain why it has been so
difficult to find a specific kinase inhibitor that prevents
phosphorylation of the transporter in response to all stimuli.
There is no master CT-kinase. As discussed above, inhib-
itors of PKA, PKC, PKG and casein kinase II have little
effect on resting cotransport activity, suggesting that none of
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these kinases are the major CT-kinase active at rest in ferret
red cells. The properties of a volume-sensitive CT-kinase,
regulated by phosphorylation, have been described in duck
red cells [60]. In shrunken endothelial cells, c-Jun NH2-
terminal kinase (JNK) becomes activated and this kinase has
been shown to phosphorylate fusion proteins made of the
amino and carboxy cytoplasmic domains of NKCC1 in vitro
[89]. Thus JNK could be the CT-kinase that phosphorylates
and activates the cotransporter in response to cell shrinkage.
However, it has still to be established whether JNK can
phosphorylate the cotransporter in the cell. Further evidence
that JNK plays a role in the cell’s response to volume
changes is the finding that hypertonic activation of Na/H
exchange in Xenopus oocytes involves activation of JNK
[90]. In mammalian cells, hypertonicity has been shown to
activate three MAP kinase pathways, JNK, ERK and p38
[91,92] causing changes in solute transport. Interestingly,
SB203580, an inhibitor of p38 MAP kinase, and PD98059,
an inhibitor of p42/p44 MAP kinase, have no effects on
resting or arsenite-stimulated Na–K–2Cl cotransport in
ferret red cells [80].
8. Regulation by intracellular Cl
Epithelial fluxes mediated by Na–K–2Cl cotransporters
can be matched to those through channels by the concen-
trations of Na+ and Cl inside the cell, and by their
thermodynamic gradients across the membrane. Intracellular
Cl was suggested to play a particularly important role in
the regulation of cotransport in these tissues [1] and had
been found to affect Cl transport in squid axons [4,93]. In
epithelia, secretion may be initiated by the opening of apical
Cl channels. Cell Cl concentration falls and directly
enhances Cl entry on the Na–K–2Cl cotransporter as
the inward Cl gradient across the basolateral membrane
increases. However, changes in intracellular Cl concen-
tration have additional effects on the transporter, some of
which are mediated by changes in transporter phosphoryla-
tion. This is important as it means that cotransporter activity
does not blindly follow Cl level, but is coordinated with
other regulatory inputs.
Cotransporter stimulation by apically applied UTP is
secondary to a fall in cell Cl concentration in dog
tracheal epithelia [54,94]. UTP binds to a P2-purinergic
receptor to activate apical Cl channels and Cl leaves the
epithelium. The fall in Cl activates basolateral Na–K–
2Cl cotransporters mainly through an increase in their
phosphorylation measured by 32P incorporation into immu-
noprecipitated NKCC1. Cell Cl reduction alone (without
UTP), achieved by incubating cells in media containing
nystatin and low Cl, also causes parallel changes in
cotransporter activation and phosphorylation. Similar
observations have been made in shark rectal gland [55].
These glands secrete in response to secretogogues that
raise cAMP levels (e.g. forskolin), and this secretion is
accompanied by increased cotransporter activity and phos-
phorylation. An obvious explanation is that the cotrans-
porter is phosphorylated by PKA, however, shark NKCC1
lacks a consensus site for phosphorylation by PKA [13].
Fig. 3. Multiple kinase and phosphatase model for cotransporter regulation. The cotransporter can be phosphorylated (COT-P1, COT-P2, COT-P3, COT-Pn)
and activated by several kinases (CT-K1, CT-K2, CT-K3, CT-Kn) and dephosphorylated by several phosphatases (CT-PPase1, CT-PPase2, CT-PPase3, CT-
PPasen). Possible sites for the actions of PP1, staurosporine, arsenite, calyculin A, and deoxygenation are shown. CT-PPase1 may be protein phosphatase 1, and
CT-PPase3 protein phosphatase 2C (inhibition by low Mg2 + concentration is indicated) [88]. Other abbreviations as in Figs. 1 and 2.
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Further investigation showed that the cotransporter was
neither phosphorylated nor activated under conditions that
prevented changes in cell Cl content in response to
secretogogues, suggesting that intracellular Cl is the key
intermediary and works mainly by affecting cotransporter
phosphorylation.
Further evidence for the importance of intracellular Cl
in regulating the cotransporter comes from studies on the
expression of the K–Cl cotransporter (KCC1) in HEK-293
cells [95]. Overexpression of KCC1 leads to a depletion of
cell Cl and this activates endogenous Na–K–2Cl cotrans-
porters. A steep relationship between cell Cl concentration
and Na–K–2Cl cotransporter rate was found over the
physiological range.
In endothelial cells, although hypertonic shrinkage acti-
vates unidirectional (possibly exchange) fluxes through the
cotransporter, net fluxes are not produced [31,96]. This has
led to the suggestion that intracellular Cl (concentration
rises on hypertonic shrinkage) slows the rate at which ion
binding sites on the fully unloaded transporter gain access
to the external medium, thus inhibiting net influx but still
permitting exchange fluxes (measured with 86Rb) [31,50].
The cotransporter in cells from the trabecular meshwork
of the human eye is also very sensitive to changes in cell
Cl concentration (stimulated by a fall in cell Cl) and
volume [97]. These two stimuli appear to act independently
of each other.
The mechanisms described above attempt to clamp cell
Cl at a particular value, an appropriate response for a
mature cell. However, during growth and development,
there must be mechanisms that allow uptake of ions with
less inhibition from intracellular Cl. Growth factors, for
instance serum, stimulate the Na–K–2Cl cotransporter to
increase cell ion content. However, this stimulation is not
accompanied by changes in NKCC1 phosphorylation, nor
by a fall of cell Cl content (but rather by a slight increase)
[50]. It was suggested that serum might alter the Cl set
point of the transporter so that it is less sensitive to
inhibition by intracellular Cl. How this change in set point
is brought about is not clear. One possibility is that cells
contain a Cl sensing protein, the activity of which is
altered by serum. This protein interacts with the cotrans-
porter so that it is disinhibited from mediating a net inward
movement of ions.
9. Interactions with the cytoskeleton
It has long been speculated that the actin-based cytos-
keleton might be involved in cotransporter regulation [71].
An early observation was that a 230 kDa protein, goblin,
was phosphorylated when cotransport was stimulated in
turkey red cells by isoprenaline [98]. The time courses of
activation of cotransport and phosphorylation were similar,
and both responded in similar ways to pharmacological
interventions. It later transpired that goblin is similar to the
mammalian cytoskeletal protein ankyrin [71]. This clearly
showed that phosphorylation of a cytoskeletal protein
affects cotransporter function.
Studies on gut epithelial cells suggest that there are two
main pathways that regulate cotransport in response to
secretogogues which increase cAMP levels (e.g. forskolin).
Their relative influence varies with cell type. One route
involves direct effects of PKA and the other relies on a fall
of cell Cl concentration that causes both phosphorylation
of the cotransporter and a reorganization of the cytoskele-
ton [49,94,99,100]. Secretogogues that increase cell cAMP
levels usually activate apical Cl channels in gut epithelia
and also activate basolateral NKCC1 and cause remodel-
ling of basolateral F-actin. Agents that stabilize F-actin
(e.g. phalloidin and jasplakinolide) reduce cAMP-mediated
stimulation of Na–K–2Cl cotransport [99–101]. On the
other hand, cytochalasin D, which promotes disassembly
of the cytoskeleton, activates the cotransporter whereas
latrunculin A, which binds to G-actin preventing polymer-
isation and thus keeping actin in a monomeric form, has
no effect on transport suggesting that short filaments of
actin activate the cotransporter [101]. By comparing the
responses of HT29 cell lines that respond to cAMP with a
fall in cell Cl concentration with those in which Cl does
not change, it was concluded that stabilization of the
cytoskeleton prevents cotransport stimulation by the Cl-
dependent route, but not by the cAMP-dependent route
[100]. However, in cells that respond to cAMP with a fall
in Cl concentration, phalloidin did not prevent a con-
comitant increase in bumetanide binding. Such an increase
may indicate either an increase in the number of cotrans-
porter molecules in the membrane, or an increase in
cotransporter phosphorylation [36]. This suggests that in-
teractions with the actin cytoskeleton can override the in-
fluence of either increased transporter phosphorylation or
cotransporter number.
In T84 cells, forskolin does not affect the number of
cotransporters in the cell membrane, judged either by anti-
body or bumetanide binding, but it does substantially in-
crease the surface expression of two proteins (130 and 160
kDa) which co-precipitate with the cotransporter [12].
Preloading cells with phalloidin reduces the expression of
these proteins.
Phalloidin has little effect on cotransport stimulated in
T84 cells by hypertonicity but does markedly inhibit
cotransport stimulated by hypotonicity (fall of cell Cl
concentration?) [49]. In both cases, increased basolateral
cotransport is not accompanied by changes in apical Cl
secretion indicating that apical and basolateral transporters
can be regulated independently of each other. It also shows
that cotransporter activation per se is not sufficient to
activate secretion. A similar conclusion was reached in
studies of cotransport stimulation by calyculin in shark
rectal gland [55].
In vascular endothelial cells, inhibition of myosin light
chain kinase (MLCK) with ML-7 prevents both phosphory-
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lation of myosin light chains and activation of cotransport
on cell shrinkage [10]. However, ML-7 has no effect on
shrinkage-induced cotransporter phosphorylation. Again,
interactions with the cytoskeleton override the effects of
cotransporter phosphorylation. ML-7 also inhibits the stim-
ulation of cotransport caused by shrinking Ehrlich ascites
cells suggesting a role for MLCK in the regulation of
NKCC1 during RVI [61]. Brief treatment of these cells
with cytochalasin B produces membrane blebs that lack
actin and myosin and in which the cotransporter is perma-
nently and partially activated under isotonic conditions
[62,102,103]. It is not possible to activate the transporter
further by shrinking the blebs nor does ML-7 have any
effect on transport [62].
Similar interactions with myosin have been observed in
T84 cells [104]. In this case, inhibition of MLCK with
ML-7, or inhibition of myosin ATPase with butanedione
monoxime, prevents the stimulation of cotransport by
cAMP, suggesting that contraction of actin-myosin is
required for cotransporter activation under these condi-
tions. Recently, it has been demonstrated that the contrac-
tile state of vascular smooth muscle affects cotransport
[105]. Phenylephrine causes both contraction of the muscle
and activation of cotransport. However, cotransport activa-
tion is prevented if the muscle is stretched by more than
10% and prevented from shortening. Nitrovasodilators
inhibit cotransport and reduce NKCC1 phosphorylation
[106].
10. Does oligomerization of the cotransporter play a role
in transport regulation?
The Na–K–2Cl cotransporter and other members of the
CCC family appear readily to form stable complexes with
themselves and other proteins. These complexes may be
important in regulating transport. Phosphorylation of ele-
ments of the cytoskeleton can affect cotransport activity
independently of the cotransporter’s own phosphorylation
state, suggesting that protein–protein interactions are
important in cotransport regulation. Expression of inactive
Na–K–2Cl cotransporter mutants in translation systems
often suppresses the activity of the endogenous NKCC
[39], again suggesting protein–protein interactions, and the
cotransporter forms complexes with one of its own regu-
latory enzymes, protein phosphatase 1 [48]. Studies using
reversible chemical cross-linking of proteins indicate that
NKCC1 probably exists as a homodimer in membranes
from salivary glands and HEK293 cells [107]. These
homodimers are stable in mild detergents like 0.3% Triton
X-100 and 20 mM deoxycholate but are disrupted by SDS.
Early studies on furosemide binding proteins (including
CCC family members) isolated from Ehrlich ascites cells,
analysed on non-reducing gels and following chemical
cross-linking, also suggest that these proteins normally
exist as homodimers [108].
High molecular weight complexes have been observed
when proteins from ferret red cells membranes are separated
by SDS-PAGE and on non-denaturing gels (blue-native-gel
electrophoresis). They are also seen when proteins, immu-
noprecipitated from ferret red cell membranes with cotrans-
porter antibody T4, are separated by SDS-PAGE [79]. These
complexes, whether in membranes or immunoprecipitates,
are very stable, surviving boiling in SDS and reducing
agents. Their molecular weights, 340, 470 and 600 kDa
are consistent with the cotransporter forming dimers, trimers
and possibly tetramers, though it is possible that other
proteins are involved.
Formation of complexes by members of the CCC family
may alter transport properties. The newly discovered CIP1
does not transport ions itself but associates with NKCC1 to
inhibit transport [20]. It does not inhibit transport by
NKCC2 or KCC1. Carboxy-terminal-truncated splice var-
iants of NKCC2 associate with full-length NKCC2 to inhibit
transport [18], and this inhibition is reduced if the proteins
are phosphorylated by PKA [109]. One of these truncated
variants transports Na+ and Cl but not K+ under hypotonic
conditions [26]. Thus, cAMP switches the transport proper-
ties of TAL cells: at low levels, the truncated variant is
active, and cells reabsorb Na+ and Cl independently of K+,
whereas at higher levels, NKCC2 becomes active, and K+ is
reabsorbed along with Na+ and Cl.
K–Cl cotransporters also exist in membranes as multi-
mers [110]. Truncation of the amino end of K–Cl cotrans-
porters leads to loss of transport function, and these proteins
inhibit transport in co-expressed wild-type KCCs. Further
truncation of the carboxy-terminal of these mutants prevents
the inhibitory effect. Truncation of the carboxy-terminal
alone leads to loss of function but these proteins do not
inhibit neighbouring KCCs.
11. Conclusions and perspectives
Na–K–2Cl cotransport is influenced by a wide range of
factors. These probably influence activity through at least
three main routes operating in parallel: cotransporter phos-
phorylation, protein–protein interactions and cell Cl con-
centration. It seems unlikely that there is any one final
common pathway for control, and even with phosphoryla-
tion, it appears that the transporter can be phosphorylated in
several different ways. Protein–protein interactions can
override the effects of phosphorylation in several situations
and cell Cl concentration may directly affect transport
behaviour, possibly switching it between futile self-ex-
change and productive net transport. Important tasks for
future studies are to establish how the patterns of both
cotransporter phosphorylation and oligomerization affect
transport. Finally, with the development of techniques such
as mass spectrometry, it should be possible to assess how
other post-translational changes to cotransporter structure
affect function.
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